1
|
Zhang Y, Hao H, Lin J, Ma Z, Li H, Nie Z, Cui Y, Guo Z, Zhang Y, Wang X, Tang R. Conformation-Stabilized Amorphous Nanocoating for Rational Design of Long-Term Thermostable Viral Vaccines. ACS APPLIED MATERIALS & INTERFACES 2022; 14:39873-39884. [PMID: 36018064 DOI: 10.1021/acsami.2c12065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Despite the great potency of vaccines to combat infectious diseases, their global use is hindered by a lack of thermostability, which leads to a constant need for cold-chain storage. Here, aiming at long-term thermostability and eliminating cold-chain requirements of bioactive vaccines, we propose that efforts should focus on tailoring the conformational stability of vaccines. Accordingly, we design a nanocoating composed of histidine (His)-coordinated amorphous Zn and 2-methylimidazolate complex (His-aZn-mIM) on single nanoparticles of viral vaccines to introduce intramolecular coordinated linkage between viruses and the nanocoatings. The coordinated nanocoating enhances the rigidity of proteins and preserves the vaccine's activity. Importantly, integrating His into the original Zn-N coordinative environment symbiotically reinforces its tolerance to biological and hydrothermal solutions, resulting in the augmented thermostability following the Hofmeister effect. Thus, even after storage of His-aZn-mIM encapsulated Human adenovirus type 5 (Ad5@His-aZn-mIM) at 25 °C for 90 d, the potency loss of the coated Ad5 is less than 10%, while the native Ad5 becomes 100% ineffective within one month. Such a nanocoating gains thermostability by forming an ultrastable hydration shell, which prevents viral proteins from unfolding under the attack of hydration ions, providing a conformational stabilizer upon heat exposure. Our findings represent an easy-access biomimetic platform to address the long-term vaccine storage without the requirement of a cold chain.
Collapse
Affiliation(s)
- Ying Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
- Qiushi Academy for Advanced Studies, Zhejiang University, Hangzhou 310027, Zhejiang, China
- Sir Run Run Shaw Hospital, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang, China
| | - Haibin Hao
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
- Qiushi Academy for Advanced Studies, Zhejiang University, Hangzhou 310027, Zhejiang, China
| | - Jiake Lin
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zaiqiang Ma
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Huixin Li
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zihao Nie
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yihao Cui
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Zhengxi Guo
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Yaqin Zhang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
| | - Xiaoyu Wang
- Qiushi Academy for Advanced Studies, Zhejiang University, Hangzhou 310027, Zhejiang, China
- Sir Run Run Shaw Hospital, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang, China
| | - Ruikang Tang
- Department of Chemistry, Zhejiang University, Hangzhou 310027, China
- Qiushi Academy for Advanced Studies, Zhejiang University, Hangzhou 310027, Zhejiang, China
- Sir Run Run Shaw Hospital, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang, China
| |
Collapse
|
2
|
Evaluation of a New Viral Vaccine Vector in Mice and Rhesus Macaques: J Paramyxovirus Expressing Hemagglutinin of Influenza A Virus H5N1. J Virol 2021; 95:e0132121. [PMID: 34469242 DOI: 10.1128/jvi.01321-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
H5N1, an avian influenza virus, is known to circulate in many Asian countries, such as Bangladesh, China, Cambodia, Indonesia, and Vietnam. The current FDA-approved H5N1 vaccine has a moderate level of efficacy. A safe and effective vaccine is needed to prevent outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in humans. Nonsegmented negative-sense single-stranded viruses (NNSVs) are widely used as a vector to develop vaccines for humans, animals, and poultry. NNSVs stably express foreign genes without integrating with the host genome. J paramyxovirus (JPV) is a nonsegmented negative-strand RNA virus and a member of the proposed genus Jeilongvirus in the family Paramyxoviridae. JPV-specific antibodies have been detected in rodents, bats, humans, and pigs, but the virus is not associated with disease in any species other than mice. JPV replicates in the respiratory tract of mice and efficiently expresses the virus-vectored foreign genes in tissue culture cells. In this work, we explored JPV as a vector for developing an H5N1 vaccine using intranasal delivery. We incorporated hemagglutinin (HA) of H5N1 into the JPV genome by replacing the small hydrophobic (SH) gene to generate a recombinant JPV expressing HA (rJPV-ΔSH-H5). A single intranasal administration of rJPV-ΔSH-H5 protected mice from a lethal HPAI H5N1 challenge. Intranasal vaccination of rJPV-ΔSH-H5 in rhesus macaques elicited antigen-specific humoral and cell-mediated immune responses. This work demonstrates that JPV is a promising vaccine vector. IMPORTANCE A highly pathogenic avian influenza (HPAI) H5N1 outbreak in Southeast Asia destroyed millions of birds. Transmission of H5N1 into humans resulted in deaths in many countries. In this work, we developed a novel H5N1 vaccine candidate using J paramyxovirus (JPV) as a vector and demonstrated that JPV is an efficacious vaccine vector in animals. Nonsegmented negative-sense single-stranded viruses (NNSVs) stably express foreign genes without integrating into the host genome. JPV, an NNSV, replicates efficiently in the respiratory tract and induces robust immune responses.
Collapse
|
3
|
Tang J, Yin D, Wang R, Zhou Q, Zhou X, Xing X, Liu HM, Liu G, Wang G. A recombinant adenovirus expressing the E protein of duck Tembusu virus induces protective immunity in duck. J Vet Med Sci 2018; 81:314-320. [PMID: 30584200 PMCID: PMC6395196 DOI: 10.1292/jvms.18-0036] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Duck Tembusu virus disease, caused by the duck Tembusu virus (DTMUV), can lead to a
severe reduction in egg production and growth retardation in laying ducks and ducklings,
respectively. In this study, we engineered a novel recombinant adenovirus expressing the E
protein of DTMUV (rAd-E) in AAV-293 cells (analyzed by western blot and indirect
immunofluorescence assays). Intramuscular immunization of Cherry Valley ducks with rAd-E
was performed to evaluate host cellular and humoral immune responses. Compared to the
phosphate-buffered saline administered group and the negative control wild-type adenovirus
(wtAd) group, the rAd-E vaccinated group showed increased cellular and humoral responses.
The results from the cytokine release and lymphocyte proliferation assays showed that
rAd-E induced a stronger cellular immune response than the control group
(P<0.01), 4 weeks after primary immunization. The results of
enzyme-linked immunosorbent and virus neutralization assays showed that rAd-E induced
higher titers of specific neutralizing antibodies, 2 weeks after primary immunization. The
DTMUV challenge experiment showed a higher survival rate (80%) of ducks in the rAd-E
group, when challenged with 0.5 ml
(ELD50=10−2.67/0.2 ml) of the DTMUV strain AH-F10.
These results indicate that rAd-E effectively protects ducks against DTMUV infection.
Therefore, rAd-E could be a vaccine candidate to provide an effective and safe method for
prevention and control of DTMUV infection.
Collapse
Affiliation(s)
- Jingyu Tang
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.,Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China
| | - Dongdong Yin
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.,Anhui Province Key Laboratory of Veterinary Pathobiology and Disease Control, Hefei 230036, China
| | - Rui Wang
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.,Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China
| | - Qi Zhou
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China
| | - Xiaoya Zhou
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China
| | - Xue Xing
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China
| | - Hong-Mei Liu
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.,Anhui Province Key Laboratory of Veterinary Pathobiology and Disease Control, Hefei 230036, China
| | - Guangqing Liu
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China
| | - Guijun Wang
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230036, China.,Anhui Province Key Laboratory of Veterinary Pathobiology and Disease Control, Hefei 230036, China
| |
Collapse
|
4
|
|
5
|
Pelliccia M, Andreozzi P, Paulose J, D'Alicarnasso M, Cagno V, Donalisio M, Civra A, Broeckel RM, Haese N, Jacob Silva P, Carney RP, Marjomäki V, Streblow DN, Lembo D, Stellacci F, Vitelli V, Krol S. Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months. Nat Commun 2016; 7:13520. [PMID: 27901019 PMCID: PMC5141364 DOI: 10.1038/ncomms13520] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 10/12/2016] [Indexed: 11/29/2022] Open
Abstract
Up to 80% of the cost of vaccination programmes is due to the cold chain problem (that is, keeping vaccines cold). Inexpensive, biocompatible additives to slow down the degradation of virus particles would address the problem. Here we propose and characterize additives that, already at very low concentrations, improve the storage time of adenovirus type 5. Anionic gold nanoparticles (10−8–10−6 M) or polyethylene glycol (PEG, molecular weight ∼8,000 Da, 10−7–10−4 M) increase the half-life of a green fluorescent protein expressing adenovirus from ∼48 h to 21 days at 37 °C (from 7 to >30 days at room temperature). They replicate the known stabilizing effect of sucrose, but at several orders of magnitude lower concentrations. PEG and sucrose maintained immunogenicity in vivo for viruses stored for 10 days at 37 °C. To achieve rational design of viral-vaccine stabilizers, our approach is aided by simplified quantitative models based on a single rate-limiting step. Keeping viral vaccines cold from the manufacturers to patients is problematic and costly. Here, Krol and others show additives that can significantly improve at very low concentrations the storage of adenovirus type 5 at ambient and elevated temperature.
Collapse
Affiliation(s)
- Maria Pelliccia
- European School of Molecular Medicine (SEMM), IFOM-IEO-Campus, via Adamello 16, Milan 20139, Italy.,Università degli Studi di Milano, Milan 20122, Italy.,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IFOM-IEO-campus, via Adamello 16, Milan 20139, Italy
| | - Patrizia Andreozzi
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IFOM-IEO-campus, via Adamello 16, Milan 20139, Italy
| | - Jayson Paulose
- Instituut-Lorentz for theoretical physics, Leiden University, 271, Niels Bohrweg 2, NL 2333 CA Leiden, The Netherlands
| | - Marco D'Alicarnasso
- European School of Molecular Medicine (SEMM), IFOM-IEO-Campus, via Adamello 16, Milan 20139, Italy.,Università degli Studi di Milano, Milan 20122, Italy.,Fondazione CEN-European Centre for Nanomedicine, Piazza Leonardo da Vinci, 32, 20133 Milan, Italy
| | - Valeria Cagno
- Laboratory of Molecular Virology and Antiviral Research, Department of Clinical and Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Italy
| | - Manuela Donalisio
- Laboratory of Molecular Virology and Antiviral Research, Department of Clinical and Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Italy
| | - Andrea Civra
- Laboratory of Molecular Virology and Antiviral Research, Department of Clinical and Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Italy
| | - Rebecca M Broeckel
- Vaccine &Gene Therapy Institute, Oregon Health &Science University, 505 NW 185th Avenue, Beaverton, Oregon 97006, USA
| | - Nicole Haese
- Vaccine &Gene Therapy Institute, Oregon Health &Science University, 505 NW 185th Avenue, Beaverton, Oregon 97006, USA
| | - Paulo Jacob Silva
- Institute of Materials and Interfaculty Bioengineering Institute, École polytechnique fédérale de Lausanne, STI IMX SUNMIL MXG 030, Station 12, CH-1015 Lausanne, Switzerland
| | - Randy P Carney
- Institute of Materials and Interfaculty Bioengineering Institute, École polytechnique fédérale de Lausanne, STI IMX SUNMIL MXG 030, Station 12, CH-1015 Lausanne, Switzerland
| | - Varpu Marjomäki
- Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskyla, Survontie 9, 40500 Jyväskyla, Finland
| | - Daniel N Streblow
- Vaccine &Gene Therapy Institute, Oregon Health &Science University, 505 NW 185th Avenue, Beaverton, Oregon 97006, USA
| | - David Lembo
- Laboratory of Molecular Virology and Antiviral Research, Department of Clinical and Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Italy
| | - Francesco Stellacci
- Institute of Materials and Interfaculty Bioengineering Institute, École polytechnique fédérale de Lausanne, STI IMX SUNMIL MXG 030, Station 12, CH-1015 Lausanne, Switzerland
| | - Vincenzo Vitelli
- Instituut-Lorentz for theoretical physics, Leiden University, 271, Niels Bohrweg 2, NL 2333 CA Leiden, The Netherlands
| | - Silke Krol
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IFOM-IEO-campus, via Adamello 16, Milan 20139, Italy.,Laboratory of Translational Nanotechnology, I.R.C.C.S. Istituto Tumori Giovanni Paolo II, viale Orazio, Flacco 65, Bari 70124, Italy
| |
Collapse
|
6
|
Abstract
Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.
Collapse
Affiliation(s)
- Rory D de Vries
- a Department of Viroscience , Erasmus MC , Rotterdam , The Netherlands
| | | |
Collapse
|
7
|
Bitrus Y, Andrew JN, Owolodun OA, Luka PD, Umaru DA. The reoccurrence of H5N1 outbreaks necessitates the development of safe and effective influenza vaccine technologies for the prevention and control of avian influenza in Sub-Saharan Africa. ACTA ACUST UNITED AC 2015. [DOI: 10.5897/bmbr2015.0246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
8
|
Choi J, Yang DK, Kim HH, Jo HY, Choi SS, Kim JT, Cho IS, Kim HW. Application of recombinant adenoviruses expressing glycoprotein or nucleoprotein of rabies virus to Korean raccoon dogs. Clin Exp Vaccine Res 2015; 4:189-94. [PMID: 26273578 PMCID: PMC4524904 DOI: 10.7774/cevr.2015.4.2.189] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 04/01/2015] [Accepted: 05/15/2015] [Indexed: 11/15/2022] Open
Abstract
Purpose A new rabies vaccine for animals, including raccoon dogs, in Korea is needed to eradicate rabies infection. In this study, we constructed two recombinant adenoviruses expressing the glycoprotein or nucleoprotein of the rabies virus (RABV). We then investigated the safety and immunogenicity of these strains in raccoon dogs, depending on inoculation route. Materials and Methods Recombinant adenoviruses expressing the glycoprotein (Ad-0910G) or nucleoprotein (Ad-0910N) of rabies were constructed in 293A cells using an adenoviral system. One-year-old raccoon dogs underwent intramuscular (IM) inoculation or oral administration of the recombinant Ad-0910G and Ad-0910N. Clinical symptoms were observed and virus-neutralizing antibodies (VNA) against RABV were measured at 0, 2, 4, and 6 weeks after the immunization. Raccoons were considered positive if VNA titers were ≥ 0.1 IU/mL. Results Raccoon dogs inoculated with the combined Ad-0910G and Ad-0910N virus via the IM route did not exhibit any clinical sign of rabies during the observation period. All raccoon dogs (n = 7) immunized IM had high VNA titers, ranging from 0.17 to 41.6 IU/mL at 2 weeks after inoculation, but 70% (7/10) of raccoon dogs administered viruses via the oral route responded by 6 weeks after administration against RABV. Conclusion Raccoon dogs inoculated with Ad-0910G and Ad-0910N viruses showed no adverse effects. Immunization with the combined Ad-0910G and Ad-0910N strains may play an important role in inducing VNA against RABV in raccoon dogs.
Collapse
Affiliation(s)
- Jiyoung Choi
- College of Veterinary Medicine, Kangwon National University, Chuncheon, Korea
| | - Dong-Kun Yang
- Viral Disease Division, Animal and Plant Quarantine Agency, MAFRA, Anyang, Korea
| | - Ha-Hyun Kim
- Viral Disease Division, Animal and Plant Quarantine Agency, MAFRA, Anyang, Korea
| | - Hyun-Ye Jo
- Viral Disease Division, Animal and Plant Quarantine Agency, MAFRA, Anyang, Korea
| | - Sung-Suk Choi
- Viral Disease Division, Animal and Plant Quarantine Agency, MAFRA, Anyang, Korea
| | - Jong-Taek Kim
- College of Veterinary Medicine, Kangwon National University, Chuncheon, Korea
| | - In-Soo Cho
- Viral Disease Division, Animal and Plant Quarantine Agency, MAFRA, Anyang, Korea
| | - Hee-Won Kim
- Wild Life Center, Gyeonggi-do Veterinary Service Laboratory, Pyeongtack, Korea
| |
Collapse
|
9
|
Lei H, Peng X, Ouyang J, Zhao D, Jiao H, Shu H, Ge X. Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets. Virus Res 2015; 196:56-9. [DOI: 10.1016/j.virusres.2014.11.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Revised: 10/10/2014] [Accepted: 11/08/2014] [Indexed: 11/30/2022]
|
10
|
Dual function of the hemagglutinin H5 fused to chicken CD154 in a potential strategy of DIVA against avian influenza disease: preliminary study. Open Vet J 2015; 5:138-47. [PMID: 26623380 PMCID: PMC4663798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2015] [Accepted: 08/17/2015] [Indexed: 11/13/2022] Open
Abstract
In this study we demonstrated that the vaccine candidate against avian influenza virus H5N1 based on the hemagglutinin H5 (HA) fused to the chicken CD154 (HACD) can also be used for differentiating infected from vaccinated animals (DIVA). As the strategy of DIVA requires at least two proteins, we obtained a variant of the nucleoprotein (NP49-375) in E. coli. After its purification by IMAC, the competence of the proteins NP49-375 and HACD as coating antigens in indirect ELISA assays were tested by using the sera of chickens immunized with the proteins HA and HACD and the reference sera from several avian influenza subtypes. Together with these sera, the sera from different species of birds and the sera of chickens infected with other avian viral diseases were analyzed by competition ELISA assays coated with the proteins NP49-375 and HACD. The results showed that the segment CD154 in the chimeric protein HACD did not interfere with the recognition of the molecule HA by its specific antibodies. Also, we observed variable detection levels when the reference sera were analyzed in the ELISA plates coated with the protein NP49-375. Moreover, only the antibodies of the reference serum subtype H5 were detected in the ELISA plates coated with the protein HACD. The competition ELISA assays showed percentages of inhibition of 88-91% for the positives sera and less than 20% for the negative sera. We fixed the cut-off value of these assays at 25%. No antibody detection was observed in the sera from different species of birds or the sera of chickens infected with other avian viral diseases. This study supported the fact that the ELISA assays using the proteins NP49-375 and HACD could be valuable tools for avian influenza surveillance and as a strategy of DIVA for counteracting the highly pathogenic avian influenza virus H5N1 outbreaks.
Collapse
|
11
|
Carozza M, Rodrigues V, Unterfinger Y, Galea S, Coulpier M, Klonjkowski B, Thiaucourt F, Totté P, Richardson J. An adenoviral vector expressing lipoprotein A, a major antigen of Mycoplasma mycoides subspecies mycoides, elicits robust immune responses in mice. Vaccine 2014; 33:141-8. [PMID: 25444801 DOI: 10.1016/j.vaccine.2014.10.088] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2014] [Revised: 10/28/2014] [Accepted: 10/30/2014] [Indexed: 10/24/2022]
Abstract
Contagious bovine pleuropneumonia (CBPP), caused by Mycoplasma mycoides subsp. mycoides small colony type (MmmSC), is a devastating respiratory disease of cattle. In sub-Saharan Africa, where CBPP is enzootic, live attenuated vaccines are deployed but afford only short-lived protection. In cattle, recovery from experimental MmmSC infection has been associated with the presence of CD4(+) T lymphocytes that secrete interferon gamma in response to MmmSC, and in particular to the lipoprotein A (LppA) antigen. In an effort to develop a better vaccine against CBPP, a viral vector (Ad5-LppA) that expressed LppA was generated from human adenovirus type 5. The LppA-specific immune responses elicited by the Ad5-LppA vector were evaluated in mice, and compared to those elicited by recombinant LppA formulated with a potent adjuvant. Notably, a single administration of Ad5-LppA, but not recombinant protein, sufficed to elicit a robust LppA-specific humoral response. After a booster administration, both vector and recombinant protein elicited strong LppA-specific humoral and cell-mediated responses. Ex vivo stimulation of splenocytes induced extensive proliferation of CD4(+) T cells for mice immunized with vector or protein, and secretion of T helper 1-associated and proinflammatory cytokines for mice immunized with Ad5-LppA. Our study - by demonstrating the potential of a viral-vectored prototypic vaccine to elicit prompt and robust immune responses against a major antigen of MmmSC - represents a first step in developing a recombinant vaccine against CBPP.
Collapse
Affiliation(s)
- Marlène Carozza
- Centre International de Recherche en Agronomie pour le Développement, UMR CMAEE, Montpellier, France; INRA, UMR 1309 CMAEE, Montpellier, France; INRA, UMR 1161 Virologie, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; ANSES, UMR Virologie, 23 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMR Virologie, Maisons-Alfort F-94704, France
| | - Valérie Rodrigues
- Centre International de Recherche en Agronomie pour le Développement, UMR CMAEE, Montpellier, France; INRA, UMR 1309 CMAEE, Montpellier, France
| | - Yves Unterfinger
- INRA, UMR 1161 Virologie, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; ANSES, UMR Virologie, 23 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMR Virologie, Maisons-Alfort F-94704, France
| | - Sandra Galea
- INRA, UMR 1161 Virologie, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; ANSES, UMR Virologie, 23 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMR Virologie, Maisons-Alfort F-94704, France
| | - Muriel Coulpier
- INRA, UMR 1161 Virologie, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; ANSES, UMR Virologie, 23 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMR Virologie, Maisons-Alfort F-94704, France
| | - Bernard Klonjkowski
- INRA, UMR 1161 Virologie, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; ANSES, UMR Virologie, 23 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMR Virologie, Maisons-Alfort F-94704, France
| | - François Thiaucourt
- Centre International de Recherche en Agronomie pour le Développement, UMR CMAEE, Montpellier, France; INRA, UMR 1309 CMAEE, Montpellier, France
| | - Philippe Totté
- Centre International de Recherche en Agronomie pour le Développement, UMR CMAEE, Montpellier, France; INRA, UMR 1309 CMAEE, Montpellier, France
| | - Jennifer Richardson
- INRA, UMR 1161 Virologie, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; ANSES, UMR Virologie, 23 avenue du Général de Gaulle, 94700 Maisons-Alfort, France; Université Paris-Est, Ecole Nationale Vétérinaire d'Alfort, UMR Virologie, Maisons-Alfort F-94704, France.
| |
Collapse
|
12
|
Virus-vectored influenza virus vaccines. Viruses 2014; 6:3055-79. [PMID: 25105278 PMCID: PMC4147686 DOI: 10.3390/v6083055] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Revised: 07/28/2014] [Accepted: 07/29/2014] [Indexed: 12/16/2022] Open
Abstract
Despite the availability of an inactivated vaccine that has been licensed for >50 years, the influenza virus continues to cause morbidity and mortality worldwide. Constant evolution of circulating influenza virus strains and the emergence of new strains diminishes the effectiveness of annual vaccines that rely on a match with circulating influenza strains. Thus, there is a continued need for new, efficacious vaccines conferring cross-clade protection to avoid the need for biannual reformulation of seasonal influenza vaccines. Recombinant virus-vectored vaccines are an appealing alternative to classical inactivated vaccines because virus vectors enable native expression of influenza antigens, even from virulent influenza viruses, while expressed in the context of the vector that can improve immunogenicity. In addition, a vectored vaccine often enables delivery of the vaccine to sites of inductive immunity such as the respiratory tract enabling protection from influenza virus infection. Moreover, the ability to readily manipulate virus vectors to produce novel influenza vaccines may provide the quickest path toward a universal vaccine protecting against all influenza viruses. This review will discuss experimental virus-vectored vaccines for use in humans, comparing them to licensed vaccines and the hurdles faced for licensure of these next-generation influenza virus vaccines.
Collapse
|
13
|
Nielsen KN, Steffensen MA, Christensen JP, Thomsen AR. Priming of CD8 T cells by adenoviral vectors is critically dependent on B7 and dendritic cells but only partially dependent on CD28 ligation on CD8 T cells. THE JOURNAL OF IMMUNOLOGY 2014; 193:1223-32. [PMID: 24951814 DOI: 10.4049/jimmunol.1400197] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Adenoviral vectors have long been forerunners in the development of effective CD8 T cell-based vaccines; therefore, it is imperative that we understand the factors controlling the induction of robust and long-lasting transgene-specific immune responses by these vectors. In this study, we investigated the organ sites, molecules, and cell subsets that play a critical role in the priming of transgene-specific CD8 T cells after vaccination with a replication-deficient adenoviral vector. Using a human adenovirus serotype 5 (Ad5) vector and genetically engineered mice, we found that CD8(+) and/or CD103(+) dendritic cells in the draining lymph node played a critical role in the priming of Ad5-induced CD8 T cell responses. Moreover, we found that CD80/86, but not CD28, was essential for efficient generation of both primary effectors and memory CD8 T cells. Interestingly, the lack of CD28 expression resulted in a delayed primary response, whereas memory CD8 T cells generated in CD28-deficient mice appeared almost normal in terms of both phenotype and effector cytokine profile, but they exhibited a significantly reduced proliferative capacity upon secondary challenge while retaining immediate in vivo effector capabilities: in vivo cytotoxicity and short-term in vivo protective capacity. Overall, our data point to an absolute requirement for professional APCs and the expression of the costimulatory molecules CD80/86 for efficient CD8 T cell priming by adenoviral vectors. Additionally, our results suggest the existence of an alternative receptor for CD80/86, which may substitute, in part, for CD28.
Collapse
Affiliation(s)
- Karen N Nielsen
- Department of International Health, Immunology, and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark
| | - Maria A Steffensen
- Department of International Health, Immunology, and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark
| | - Jan P Christensen
- Department of International Health, Immunology, and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark
| | - Allan R Thomsen
- Department of International Health, Immunology, and Microbiology, University of Copenhagen, DK-2200 Copenhagen, Denmark
| |
Collapse
|
14
|
Lei H, Peng X, Shu H, Zhao D. Intranasal immunization with live recombinantLactococcus lactiscombined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus. J Med Virol 2014; 87:39-44. [DOI: 10.1002/jmv.23983] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/06/2014] [Indexed: 11/09/2022]
Affiliation(s)
- Han Lei
- Department of Biotechnology; College of Life Science and Food Engineering; Nanchang University; Nanchang Jiangxi China
| | - Xiaojue Peng
- Department of Biotechnology; College of Life Science and Food Engineering; Nanchang University; Nanchang Jiangxi China
| | - Handing Shu
- Department of Biotechnology; College of Life Science and Food Engineering; Nanchang University; Nanchang Jiangxi China
| | - Daxian Zhao
- Department of Biotechnology; College of Life Science and Food Engineering; Nanchang University; Nanchang Jiangxi China
| |
Collapse
|
15
|
Lukashevich IS, Shirwan H. Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines. NOVEL TECHNOLOGIES FOR VACCINE DEVELOPMENT 2014. [PMCID: PMC7121347 DOI: 10.1007/978-3-7091-1818-4_8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Emerging and reemerging infectious diseases as well as cancer pose great global health impacts on the society. Vaccines have emerged as effective treatments to prevent or reduce the burdens of already developed diseases. This is achieved by means of activating various components of the immune system to generate systemic inflammatory reactions targeting infectious agents or diseased cells for control/elimination. DNA virus-based genetic vaccines gained significant attention in the past decades owing to the development of DNA manipulation technologies, which allowed engineering of recombinant viral vectors encoding sequences for foreign antigens or their immunogenic epitopes as well as various immunomodulatory molecules. Despite tremendous progress in the past 50 years, many hurdles still remain for achieving the full clinical potential of viral-vectored vaccines. This chapter will present the evolution of vaccines from “live” or “attenuated” first-generation agents to recombinant DNA and viral-vectored vaccines. Particular emphasis will be given to human adenovirus (Ad) for the development of prophylactic and therapeutic vaccines. Ad biological properties related to vaccine development will be highlighted along with their advantages and potential hurdles to be overcome. In particular, we will discuss (1) genetic modifications in the Ad capsid protein to reduce the intrinsic viral immunogenicity, (2) antigen capsid incorporation for effective presentation of foreign antigens to the immune system, (3) modification of the hexon and fiber capsid proteins for Ad liver de-targeting and selective retargeting to cancer cells, (4) Ad-based vaccines carrying “arming” transgenes with immunostimulatory functions as immune adjuvants, and (5) oncolytic Ad vectors as a new therapeutic approach against cancer. Finally, the combination of adenoviral vectors with other non-adenoviral vector systems, the prime/boost strategy of immunization, clinical trials involving Ad-based vaccines, and the perspectives for the field development will be discussed.
Collapse
Affiliation(s)
- Igor S Lukashevich
- Department of Pharmacology and Toxicolog Department of Microbiology and Immunolog, University of Louisville, Louisville, Kentucky USA
| | - Haval Shirwan
- Department of Microbiology and Immunolog, University of Louisville, Louisville, Kentucky USA
| |
Collapse
|
16
|
van Els C, Mjaaland S, Næss L, Sarkadi J, Gonczol E, Smith Korsholm K, Hansen J, de Jonge J, Kersten G, Warner J, Semper A, Kruiswijk C, Oftung F. Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother 2014; 10:1935-48. [PMID: 25424803 PMCID: PMC4186026 DOI: 10.4161/hv.28639] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 03/14/2014] [Accepted: 03/24/2014] [Indexed: 01/02/2023] Open
Abstract
New and reemerging infectious diseases call for innovative and efficient control strategies of which fast vaccine design and development represent an important element. In emergency situations, when time is limited, identification and use of correlates of protection (COPs) may play a key role as a strategic tool for accelerated vaccine design, testing, and licensure. We propose that general rules for COP-based vaccine design can be extracted from the existing knowledge of protective immune responses against a large spectrum of relevant viral and bacterial pathogens. Herein, we focus on the applicability of this approach by reviewing the established and up-coming COPs for influenza in the context of traditional and a wide array of new vaccine concepts. The lessons learnt from this field may be applied more generally to COP-based accelerated vaccine design for emerging infections.
Collapse
Affiliation(s)
- Cécile van Els
- National Institute for Public Health and the Environment; Bilthoven, the Netherlands
| | | | - Lisbeth Næss
- Norwegian Institute of Public Health; Oslo, Norway
| | - Julia Sarkadi
- National Center for Epidemiology (NCE); Budapest, Hungary
| | - Eva Gonczol
- National Center for Epidemiology (NCE); Budapest, Hungary
| | | | - Jon Hansen
- Statens Serum Institut; Copenhagen, Denmark
| | - Jørgen de Jonge
- National Institute for Public Health and the Environment; Bilthoven, the Netherlands
| | - Gideon Kersten
- Institute for Translational Vaccinology; Bilthoven, the Netherlands
- Leiden Academic Center for Drug Research; University of Leiden; The Netherlands
| | | | | | - Corine Kruiswijk
- Institute for Translational Vaccinology; Bilthoven, the Netherlands
| | | |
Collapse
|
17
|
Krejcova L, Hynek D, Kopel P, Merlos Rodrigo MA, Adam V, Hubalek J, Babula P, Trnkova L, Kizek R. Development of a magnetic electrochemical bar code array for point mutation detection in the H5N1 neuraminidase gene. Viruses 2013; 5:1719-39. [PMID: 23860384 PMCID: PMC3738958 DOI: 10.3390/v5071719] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Revised: 06/10/2013] [Accepted: 07/01/2013] [Indexed: 12/29/2022] Open
Abstract
Since its first official detection in the Guangdong province of China in 1996, the highly pathogenic avian influenza virus of H5N1 subtype (HPAI H5N1) has reportedly been the cause of outbreaks in birds in more than 60 countries, 24 of which were European. The main issue is still to develop effective antiviral drugs. In this case, single point mutation in the neuraminidase gene, which causes resistance to antiviral drug and is, therefore, subjected to many studies including ours, was observed. In this study, we developed magnetic electrochemical bar code array for detection of single point mutations (mismatches in up to four nucleotides) in H5N1 neuraminidase gene. Paramagnetic particles Dynabeads® with covalently bound oligo (dT)25 were used as a tool for isolation of complementary H5N1 chains (H5N1 Zhejin, China and Aichi). For detection of H5N1 chains, oligonucleotide chains of lengths of 12 (+5 adenine) or 28 (+5 adenine) bp labeled with quantum dots (CdS, ZnS and/or PbS) were used. Individual probes hybridized to target molecules specifically with efficiency higher than 60%. The obtained signals identified mutations present in the sequence. Suggested experimental procedure allows obtaining further information from the redox signals of nucleic acids. Moreover, the used biosensor exhibits sequence specificity and low limits of detection of subnanogram quantities of target nucleic acids.
Collapse
Affiliation(s)
- Ludmila Krejcova
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
| | - David Hynek
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
| | - Pavel Kopel
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
| | - Miguel Angel Merlos Rodrigo
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
| | - Vojtech Adam
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
| | - Jaromir Hubalek
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
- Department of Microelectronics, Faculty of Electrical Engineering and Communication, Brno University of Technology, Technicka 10, Brno CZ-616 00, Czech Republic
| | - Petr Babula
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1-3, Brno CZ-612 42, Czech Republic
| | - Libuse Trnkova
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
- Department of Chemistry, Faculty of Science, Masaryk University, Kotlarska 2, Brno CZ-611 37, Czech Republic
| | - Rene Kizek
- Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic; E-Mails: (L.K.); (D.H.); (P.K.); (M.A.M.R.); (V.A.); (L.T.)
- Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ-616 00, Czech Republic; E-Mails: (J.H.); (P.B.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +420-545-133-350; Fax: +420-545-212-044
| |
Collapse
|
18
|
VP1 protein of Foot-and-mouth disease virus (FMDV) impairs baculovirus surface display. Virus Res 2013; 175:87-90. [DOI: 10.1016/j.virusres.2013.03.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2012] [Revised: 03/26/2013] [Accepted: 03/27/2013] [Indexed: 01/01/2023]
|
19
|
Pena L, Sutton T, Chockalingam A, Kumar S, Angel M, Shao H, Chen H, Li W, Perez DR. Influenza viruses with rearranged genomes as live-attenuated vaccines. J Virol 2013; 87:5118-27. [PMID: 23449800 PMCID: PMC3624320 DOI: 10.1128/jvi.02490-12] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Accepted: 02/12/2012] [Indexed: 11/20/2022] Open
Abstract
H5N1 and H9N2 avian influenza virus subtypes top the World Health Organization's list for the greatest pandemic potential. Inactivated H5N1 vaccines induce limited immune responses and, in the case of live-attenuated influenza virus vaccines (LAIV), there are safety concerns regarding the possibility of reassortment between the H5 gene segment and circulating influenza viruses. In order to overcome these drawbacks, we rearranged the genome of an avian H9N2 influenza virus and expressed the entire H5 hemagglutinin open reading frame (ORF) from the segment 8 viral RNA. These vectors had reduced polymerase activities as well as viral replication in vitro and excellent safety profiles in vivo. Immunization with the dual H9-H5 influenza virus resulted in protection against lethal H5N1 challenge in mice and ferrets, and also against a potentially pandemic H9 virus. Our studies demonstrate that rearranging the influenza virus genome has great potential for the development of improved vaccines against influenza virus as well as other pathogens.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/immunology
- Chickens
- Female
- Ferrets
- Genetic Engineering
- Genome, Viral
- Humans
- Influenza A Virus, H5N1 Subtype/genetics
- Influenza A Virus, H5N1 Subtype/immunology
- Influenza A Virus, H5N1 Subtype/physiology
- Influenza A Virus, H9N2 Subtype/genetics
- Influenza A Virus, H9N2 Subtype/immunology
- Influenza A Virus, H9N2 Subtype/physiology
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/genetics
- Influenza Vaccines/immunology
- Influenza, Human/immunology
- Influenza, Human/prevention & control
- Influenza, Human/virology
- Mice
- Mice, Inbred BALB C
- Recombination, Genetic
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/genetics
- Vaccines, Attenuated/immunology
- Virus Replication
Collapse
Affiliation(s)
- Lindomar Pena
- Department of Veterinary Medicine, University of Maryland, College Park, and Virginia-Maryland Regional College of Veterinary Medicine, College Park, Maryland, USA
| | | | | | | | | | | | | | | | | |
Collapse
|